Aug 10, 2026
Dr. Samuel Browd is a pediatric neurosurgeon, professor at the University of Washington, and Co-CEO/Chief Medical Officer of NeuFluent, a venture studio focused on neurological technologies. In this episode, we discuss his path from early neuroscience research and pediatric neurosurgery into device development, brain-computer interfaces, and the challenge of moving promising neurotechnology from universities into real clinical use.
We also explore the idea of “digital neurosurgery”: how neurosurgery still captures enormous amounts of valuable data in analog or siloed ways, why AI and computer vision may reshape surgical workflows, and how brain-computer interfaces could become a major part of neurosurgery over the next decade. Along the way, Dr. Browd reflects on startup formation, the role of venture studios, ethics around neural data, and why students entering the field today may be arriving at a uniquely important moment.
1.
Neurotechnology translation is still too
slow.
Dr. Browd argues that the
traditional path from academic discovery to clinical technology is
expensive, time-consuming, and often inefficient. Through
NeuFluent, he is trying to rethink how universities, clinicians,
engineers, strategics, and investors can work together to move
neurological technologies toward patients faster.
2.
Venture studios may offer a different model for neurotech
commercialization.
Rather than acting only like an
accelerator, NeuFluent brings together engineering, regulatory,
legal, marketing, and commercialization expertise around
neurological technologies. The goal is to evaluate market need,
development path, and exit strategy earlier, before spending years
and large amounts of capital building something without a clear
home.
3.
Neurosurgery still wastes or underuses valuable
data.
Dr. Browd describes neurosurgery as
still largely analog, even though procedures generate rich digital
data from imaging, electrophysiology, navigation, microscopes, and
intraoperative tools. He argues that much of this information is
siloed, uncaptured, or used only for immediate clinical purposes
rather than organized for computational analysis and future
innovation.
4. AI
and BCI could transform neurosurgery, but workflow
matters.
Sam emphasizes that new tools will
only be adopted if they fit naturally into clinical workflows. If a
technology adds extra steps for busy surgeons, adoption will be
limited; the opportunity is to use existing data streams and
workflows to build better systems around the surgeon rather than
burdening them.
5.
Students are entering neurotechnology at a uniquely exciting
moment.
For students interested in BCI,
neurosurgery, AI, or medical devices, Dr. Browd sees this as a rare
moment where powerful computational tools and clinical need are
converging. His advice is to “lean in” because the field now has
the potential to move faster and directly help patients in ways
that were not possible before.
0:00 Introduction to Dr. Samuel Browd, pediatric
neurosurgery, NeuFluent, and neurotechnology
0:50 Sam’s path from Gainesville to neurosurgery,
neuroscience, and device development
2:10 Early interest in Alzheimer’s disease,
epilepsy, MRI, and brain science
3:35 Pediatric neurosurgery and the long-term
impact of treating children
4:20 Seeing early Utah arrays and becoming
interested in BCI
6:10 What NeuFluent is and why neurotech may need a
venture studio model
8:50 How NeuFluent differs from a traditional
incubator or accelerator
10:40 Academic commercialization, the valley of
death, and changing university incentives
12:10 NeuFluent’s current status, patents, stealth
work, and approach to building from within
15:50 What “digital neurosurgery”
means
17:25 Creating the Foundation for Digital
Neurosurgery and organizing neurosurgery around
AI
20:30 Neurosurgical data that is currently
uncaptured, siloed, or underused
23:20 Why workflow integration determines whether
new technologies are adopted
25:30 The next 10–20 years of BCI, implantable
devices, AI, and neurosurgery
27:40 What needs to change to bring neurotechnology
to patients faster
30:50 Advice for students entering BCI,
neurosurgery, and neurotechnology
33:00 Why Sam is optimistic about AI and
neurotechnology